IL135631A0 - Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists - Google Patents

Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists

Info

Publication number
IL135631A0
IL135631A0 IL13563198A IL13563198A IL135631A0 IL 135631 A0 IL135631 A0 IL 135631A0 IL 13563198 A IL13563198 A IL 13563198A IL 13563198 A IL13563198 A IL 13563198A IL 135631 A0 IL135631 A0 IL 135631A0
Authority
IL
Israel
Prior art keywords
antagonists
substance
cyclic ether
ether compounds
trifluoromethyl cyclic
Prior art date
Application number
IL13563198A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to IL14446698A priority Critical patent/IL144466A0/xx
Publication of IL135631A0 publication Critical patent/IL135631A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76Benzo[c]pyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13563198A 1997-11-19 1998-10-26 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists IL135631A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14446698A IL144466A0 (en) 1997-11-19 1998-10-26 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19
PCT/IB1998/001704 WO1999025714A1 (en) 1997-11-19 1998-10-26 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists

Publications (1)

Publication Number Publication Date
IL135631A0 true IL135631A0 (en) 2001-05-20

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13563198A IL135631A0 (en) 1997-11-19 1998-10-26 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists

Country Status (40)

Country Link
US (2) US20030208079A1 (xx)
EP (1) EP1032571B1 (xx)
JP (2) JP3394239B2 (xx)
KR (1) KR100366902B1 (xx)
CN (1) CN1173974C (xx)
AP (1) AP909A (xx)
AR (1) AR016422A1 (xx)
AT (1) ATE219078T1 (xx)
AU (1) AU734218B2 (xx)
BG (1) BG63969B1 (xx)
CA (1) CA2310627C (xx)
CO (1) CO4771153A1 (xx)
CZ (1) CZ297315B6 (xx)
DE (1) DE69806045T2 (xx)
DK (1) DK1032571T3 (xx)
DZ (1) DZ2655A1 (xx)
EA (1) EA002621B1 (xx)
ES (1) ES2177058T3 (xx)
HK (1) HK1033313A1 (xx)
HR (1) HRP20000313B1 (xx)
HU (1) HUP0101112A3 (xx)
ID (1) ID24240A (xx)
IL (1) IL135631A0 (xx)
IS (1) IS2202B (xx)
MA (1) MA26567A1 (xx)
MY (1) MY120558A (xx)
NO (2) NO20002544L (xx)
NZ (1) NZ503912A (xx)
OA (1) OA11380A (xx)
PA (1) PA8463001A1 (xx)
PE (1) PE20000021A1 (xx)
PL (1) PL193484B1 (xx)
PT (1) PT1032571E (xx)
RS (1) RS49792B (xx)
SK (1) SK283460B6 (xx)
TN (1) TNSN98210A1 (xx)
TR (1) TR200001463T2 (xx)
TW (1) TW426667B (xx)
UA (1) UA59417C2 (xx)
WO (1) WO1999025714A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
EA200101050A1 (ru) * 1999-05-06 2002-04-25 Пфайзер Продактс Инк. Замещенные бензолактамные соединения
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
ATE234832T1 (de) * 1999-05-21 2003-04-15 Pfizer Prod Inc 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate
AU7557000A (en) * 1999-10-07 2001-05-10 Hisamitsu Pharmaceutical Co. Inc. Piperidine derivatives
PT1095939E (pt) * 1999-10-18 2004-04-30 Pfizer Prod Inc Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
DK1288208T3 (da) 2001-08-30 2006-10-16 Pfizer Prod Inc Fremgangsmåde til fremstilling af 2-(4-alkyl-1-piperazinyl)-benzaldehyd- og -benzylidenforbindelser ved nucleofil aromatisk substituering af 2-flourbenzaldehyd med 4-alkyl-1-peperazin i vand som oplösningsmiddel
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
AU2003262773A1 (en) * 2002-08-27 2004-03-19 David T. Harris Amelioration of effects of cigarette smoke
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
NO2729147T3 (xx) 2011-07-04 2018-02-03
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
US5886011A (en) * 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
DE69612003T2 (de) * 1995-07-07 2001-06-21 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
ATE234832T1 (de) * 1999-05-21 2003-04-15 Pfizer Prod Inc 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate
PT1095939E (pt) * 1999-10-18 2004-04-30 Pfizer Prod Inc Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo

Also Published As

Publication number Publication date
PL193484B1 (pl) 2007-02-28
DZ2655A1 (fr) 2003-03-22
DK1032571T3 (da) 2002-07-15
ID24240A (id) 2000-07-13
AU9454998A (en) 1999-06-07
JP2003040777A (ja) 2003-02-13
EA200000432A1 (ru) 2000-12-25
EA002621B1 (ru) 2002-06-27
NZ503912A (en) 2002-09-27
HK1033313A1 (en) 2001-08-24
PL340642A1 (en) 2001-02-12
CN1279681A (zh) 2001-01-10
MA26567A1 (fr) 2004-12-20
TR200001463T2 (tr) 2000-12-21
HUP0101112A2 (hu) 2002-05-29
HRP20000313B1 (en) 2002-04-30
CN1173974C (zh) 2004-11-03
SK283460B6 (sk) 2003-08-05
IS2202B (is) 2007-02-15
NO20002544D0 (no) 2000-05-18
SK7232000A3 (en) 2001-09-11
AP9801402A0 (en) 1998-12-31
CZ297315B6 (cs) 2006-11-15
ES2177058T3 (es) 2002-12-01
AR016422A1 (es) 2001-07-04
RS49792B (sr) 2008-06-05
ATE219078T1 (de) 2002-06-15
HUP0101112A3 (en) 2002-06-28
CO4771153A1 (es) 1999-04-30
CA2310627A1 (en) 1999-05-27
NO20002544L (no) 2000-07-17
TW426667B (en) 2001-03-21
UA59417C2 (uk) 2003-09-15
AU734218B2 (en) 2001-06-07
JP2001523680A (ja) 2001-11-27
CA2310627C (en) 2005-08-09
PE20000021A1 (es) 2000-02-25
US20050171354A1 (en) 2005-08-04
CZ20001834A3 (cs) 2001-07-11
NO20042879L (no) 2000-07-17
DE69806045D1 (en) 2002-07-18
WO1999025714A1 (en) 1999-05-27
US20030208079A1 (en) 2003-11-06
KR100366902B1 (ko) 2003-01-09
PT1032571E (pt) 2002-09-30
EP1032571B1 (en) 2002-06-12
HRP20000313A2 (en) 2000-12-31
TNSN98210A1 (fr) 2005-03-15
MY120558A (en) 2005-11-30
EP1032571A1 (en) 2000-09-06
PA8463001A1 (es) 2000-09-29
OA11380A (en) 2004-01-27
JP3394239B2 (ja) 2003-04-07
BG63969B1 (bg) 2003-08-29
AP909A (en) 2000-12-04
DE69806045T2 (de) 2002-11-14
BG104437A (en) 2001-02-28
YU29400A (sh) 2003-02-28
IS5470A (is) 2000-04-26

Similar Documents

Publication Publication Date Title
AP9801402A0 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
GB9918962D0 (en) Chemical compounds xxii
IL152209A0 (en) Benzoamide piperidine compounds as substance p antagonists
GB9705361D0 (en) Chemical compounds
GB9704208D0 (en) Chemical compounds
ZA988353B (en) New NPY antagonists
GB9826359D0 (en) Novel receptors
PL341114A1 (en) Antagonists of thrombosin receptors
EP0986553A4 (en) DIHYDROPYRIMIDONE DERIVATIVES AS NPY ANTAGONISTS
SG70655A1 (en) New spirocyclic compounds
SI1261588T1 (en) IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS
IL144466A0 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
SI1032571T1 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
GB9703201D0 (en) Chemical compounds
ZA9810544B (en) Piperidinylaminomethyl Trifluoromethyl cyclic ether compounds as substance P antagonists.
ID24694A (id) Pemakaian bentuk zat-zat sebagai katalis untuk pembuatan kaprolaktam
GB9705212D0 (en) Chemical compounds
GB9706707D0 (en) Chemical compounds
ZA200005695B (en) Process for the preparation of piperidinylaminome thyltrifluoromethyl cyclic ether compounds.
GB9706668D0 (en) Chemical compounds
GB9703136D0 (en) Chemical compounds
GB9704223D0 (en) Chemical compounds
GB9704809D0 (en) Chemical compounds
GB9704182D0 (en) Chemical compounds
GB9704151D0 (en) Chemical compounds

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees